Concurrent Treatment with Anti-DLL4 Enhances Antitumor and Proapoptotic Efficacy of a γ-Secretase Inhibitor in Gastric Cancer

Muxing Kang(Second Affiliated Hospital of Zhejiang University), Jian Chen(Second Affiliated Hospital of Zhejiang University), Xiaoli Jin(Second Affiliated Hospital of Zhejiang University), Yaoyi Zhang(Second Affiliated Hospital of Zhejiang University), Yi Huang(Children's Hospital of Chongqing Medical University), Dan Wu(Nanjing Drum Tower Hospital), Pintong Huang(Second Affiliated Hospital of Zhejiang University), Guofeng Chen(302 Military Hospital of China), Guogang Li(Second Affiliated Hospital of Zhejiang University), Jianzhen Shan(Second Affiliated Hospital of Zhejiang University)
Translational Oncology
March 16, 2018
10.1016/j.tranon.2018.02.016
Cited by 7

Related Papers

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome
|Oncotarget|2015|212
TLR8 signaling enhances tumor immunity by preventing tumor‐induced T‐cell senescence
|EMBO Molecular Medicine|2014|165
Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta‐analysis
|Hepatology|2017|160
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment
|Hepatology|2016|156